vs
礼蓝动物保健（ELAN）与Rollins, Inc.（ROL）财务数据对比。点击上方公司名可切换其他公司
礼蓝动物保健的季度营收约是Rollins, Inc.的1.3倍（$1.1B vs $906.4M），Rollins, Inc.净利率更高（11.9% vs -24.1%，领先36.0%），礼蓝动物保健同比增速更快（12.2% vs 10.2%），Rollins, Inc.自由现金流更多（$111.2M vs $46.0M），过去两年Rollins, Inc.的营收复合增速更高（0.8% vs -2.6%）
礼蓝动物保健是一家美国动物保健制药企业，专注于生产宠物及家畜用药品与疫苗。该公司原为礼来公司旗下子公司，2019年完成分拆独立，目前是全球第三大动物保健企业。
Rollins, Inc.是北美知名虫害防治服务商，面向住宅及商业客户提供专业防控服务。公司依托Orkin、HomeTeam Pest Defense等多家全资子公司布局全球业务，覆盖北美、英国等市场，在民用及商用虫害治理领域具备深厚的行业积累与品牌优势。
ELAN vs ROL — 直观对比
营收规模更大
ELAN
是对方的1.3倍
$906.4M
营收增速更快
ELAN
高出2.0%
10.2%
净利率更高
ROL
高出36.0%
-24.1%
自由现金流更多
ROL
多$65.2M
$46.0M
两年增速更快
ROL
近两年复合增速
-2.6%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $1.1B | $906.4M |
| 净利润 | $-276.0M | $107.8M |
| 毛利率 | 51.5% | — |
| 营业利润率 | -22.6% | 16.1% |
| 净利率 | -24.1% | 11.9% |
| 营收同比 | 12.2% | 10.2% |
| 净利润同比 | -3350.0% | 2.5% |
| 每股收益（稀释后） | $-0.55 | $0.22 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ELANROL
| Q1 26 | — | $906.4M | ||
| Q4 25 | $1.1B | $912.9M | ||
| Q3 25 | $1.1B | $1.0B | ||
| Q2 25 | $1.2B | $999.5M | ||
| Q1 25 | $1.2B | $822.5M | ||
| Q4 24 | $1.0B | $832.2M | ||
| Q3 24 | $1.0B | $916.3M | ||
| Q2 24 | $1.2B | $891.9M |
净利润ELANROL
| Q1 26 | — | $107.8M | ||
| Q4 25 | $-276.0M | $116.4M | ||
| Q3 25 | $-34.0M | $163.5M | ||
| Q2 25 | $11.0M | $141.5M | ||
| Q1 25 | $67.0M | $105.2M | ||
| Q4 24 | $-8.0M | $105.7M | ||
| Q3 24 | $364.0M | $136.9M | ||
| Q2 24 | $-50.0M | $129.4M |
毛利率ELANROL
| Q1 26 | — | — | ||
| Q4 25 | 51.5% | — | ||
| Q3 25 | 53.4% | — | ||
| Q2 25 | 57.5% | — | ||
| Q1 25 | 57.3% | — | ||
| Q4 24 | 50.9% | — | ||
| Q3 24 | 52.2% | — | ||
| Q2 24 | 58.2% | — |
营业利润率ELANROL
| Q1 26 | — | 16.1% | ||
| Q4 25 | -22.6% | 17.5% | ||
| Q3 25 | -4.4% | 21.9% | ||
| Q2 25 | 2.0% | 19.8% | ||
| Q1 25 | 5.0% | 17.3% | ||
| Q4 24 | -5.0% | 18.1% | ||
| Q3 24 | 54.3% | 20.9% | ||
| Q2 24 | -2.7% | 20.4% |
净利率ELANROL
| Q1 26 | — | 11.9% | ||
| Q4 25 | -24.1% | 12.8% | ||
| Q3 25 | -3.0% | 15.9% | ||
| Q2 25 | 0.9% | 14.2% | ||
| Q1 25 | 5.6% | 12.8% | ||
| Q4 24 | -0.8% | 12.7% | ||
| Q3 24 | 35.3% | 14.9% | ||
| Q2 24 | -4.2% | 14.5% |
每股收益（稀释后）ELANROL
| Q1 26 | — | $0.22 | ||
| Q4 25 | $-0.55 | $0.24 | ||
| Q3 25 | $-0.07 | $0.34 | ||
| Q2 25 | $0.02 | $0.29 | ||
| Q1 25 | $0.13 | $0.22 | ||
| Q4 24 | $-0.01 | $0.22 | ||
| Q3 24 | $0.73 | $0.28 | ||
| Q2 24 | $-0.10 | $0.27 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $545.0M | $116.5M |
| 总债务越低越好 | $3.9B | $650.6M |
| 股东权益账面价值 | $6.5B | $1.4B |
| 总资产 | $13.4B | $3.2B |
| 负债/权益比越低杠杆越低 | 0.60× | 0.47× |
8季度趋势，按日历期对齐
现金及短期投资ELANROL
| Q1 26 | — | $116.5M | ||
| Q4 25 | $545.0M | $100.0M | ||
| Q3 25 | $505.0M | $127.4M | ||
| Q2 25 | $539.0M | $123.0M | ||
| Q1 25 | $487.0M | $201.2M | ||
| Q4 24 | $468.0M | $89.6M | ||
| Q3 24 | $490.0M | $95.3M | ||
| Q2 24 | $416.0M | $106.7M |
总债务ELANROL
| Q1 26 | — | $650.6M | ||
| Q4 25 | $3.9B | $486.1M | ||
| Q3 25 | $4.0B | $485.7M | ||
| Q2 25 | $4.1B | $485.3M | ||
| Q1 25 | $4.4B | $485.5M | ||
| Q4 24 | $4.3B | $395.3M | ||
| Q3 24 | $4.4B | — | ||
| Q2 24 | $5.7B | — |
股东权益ELANROL
| Q1 26 | — | $1.4B | ||
| Q4 25 | $6.5B | $1.4B | ||
| Q3 25 | $6.7B | $1.5B | ||
| Q2 25 | $6.8B | $1.4B | ||
| Q1 25 | $6.4B | $1.4B | ||
| Q4 24 | $6.1B | $1.3B | ||
| Q3 24 | $6.5B | $1.3B | ||
| Q2 24 | $5.9B | $1.2B |
总资产ELANROL
| Q1 26 | — | $3.2B | ||
| Q4 25 | $13.4B | $3.1B | ||
| Q3 25 | $13.6B | $3.2B | ||
| Q2 25 | $13.7B | $3.2B | ||
| Q1 25 | $12.9B | $2.9B | ||
| Q4 24 | $12.6B | $2.8B | ||
| Q3 24 | $13.3B | $2.8B | ||
| Q2 24 | $13.8B | $2.8B |
负债/权益比ELANROL
| Q1 26 | — | 0.47× | ||
| Q4 25 | 0.60× | 0.35× | ||
| Q3 25 | 0.59× | 0.32× | ||
| Q2 25 | 0.61× | 0.34× | ||
| Q1 25 | 0.69× | 0.36× | ||
| Q4 24 | 0.70× | 0.30× | ||
| Q3 24 | 0.67× | — | ||
| Q2 24 | 0.96× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $108.0M | $118.4M |
| 自由现金流经营现金流 - 资本支出 | $46.0M | $111.2M |
| 自由现金流率自由现金流/营收 | 4.0% | 12.3% |
| 资本支出强度资本支出/营收 | 5.4% | 0.8% |
| 现金转化率经营现金流/净利润 | — | 1.10× |
| 过去12个月自由现金流最近4个季度 | $284.0M | $621.1M |
8季度趋势，按日历期对齐
经营现金流ELANROL
| Q1 26 | — | $118.4M | ||
| Q4 25 | $108.0M | $164.7M | ||
| Q3 25 | $219.0M | $191.3M | ||
| Q2 25 | $237.0M | $175.1M | ||
| Q1 25 | $-4.0M | $146.9M | ||
| Q4 24 | $177.0M | $188.2M | ||
| Q3 24 | $162.0M | $146.9M | ||
| Q2 24 | $200.0M | $145.1M |
自由现金流ELANROL
| Q1 26 | — | $111.2M | ||
| Q4 25 | $46.0M | $159.0M | ||
| Q3 25 | $127.0M | $182.8M | ||
| Q2 25 | $180.0M | $168.0M | ||
| Q1 25 | $-69.0M | $140.1M | ||
| Q4 24 | $130.0M | $184.0M | ||
| Q3 24 | $120.0M | $139.4M | ||
| Q2 24 | $166.0M | $136.4M |
自由现金流率ELANROL
| Q1 26 | — | 12.3% | ||
| Q4 25 | 4.0% | 17.4% | ||
| Q3 25 | 11.2% | 17.8% | ||
| Q2 25 | 14.5% | 16.8% | ||
| Q1 25 | -5.8% | 17.0% | ||
| Q4 24 | 12.7% | 22.1% | ||
| Q3 24 | 11.7% | 15.2% | ||
| Q2 24 | 14.0% | 15.3% |
资本支出强度ELANROL
| Q1 26 | — | 0.8% | ||
| Q4 25 | 5.4% | 0.6% | ||
| Q3 25 | 8.1% | 0.8% | ||
| Q2 25 | 4.6% | 0.7% | ||
| Q1 25 | 5.4% | 0.8% | ||
| Q4 24 | 4.6% | 0.5% | ||
| Q3 24 | 4.1% | 0.8% | ||
| Q2 24 | 2.9% | 1.0% |
现金转化率ELANROL
| Q1 26 | — | 1.10× | ||
| Q4 25 | — | 1.41× | ||
| Q3 25 | — | 1.17× | ||
| Q2 25 | 21.55× | 1.24× | ||
| Q1 25 | -0.06× | 1.40× | ||
| Q4 24 | — | 1.78× | ||
| Q3 24 | 0.45× | 1.07× | ||
| Q2 24 | — | 1.12× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ELAN
| Pet Health | $489.0M | 43% |
| Cattle | $296.0M | 26% |
| Poultry | $237.0M | 21% |
| Swine | $107.0M | 9% |
| Contract Manufacturing | $15.0M | 1% |
ROL
暂无分部数据
